Ulinastatin
Ulinastatin has been studied in 5 papers since 2016: 2 trials in people, 2 reviews. The newest paper, Jul 11, 2023: “Effects of anesthetic adjunctive agents on postoperative cognitive dysfunction in elderly patients undergoing noncardiac surgery: A Bayesian network meta-analysis”.
5 papers study it12 findingsUpdated
See all 5 papers on ulinastatin
At a glance
Independent labs found the same change in people. 3 independent labs in 1 country; 1 trial, none about aging.
“The U group had a lower incidence of POCD than C group (23.7 % versus 45.9 %, P = 0.043).”
None of its findings points the other way.
- 3 independent labs in 1 country
- 1 trial, none about aging
- Funders: Beijing Municipal Administration of Hospitals and 8 more
- 1 of 1 trial sponsored by its developers
- Human trial2
Studies in people
3 studies gave ulinastatin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Prevents postoperative cognitive dysfunctionOR = 0.28, 95% CI 0.10 to 0.71 | Review of trials | elderlyOlder adults | Brain and behavior, Jul 11, 2023 |
down: Decreases postoperative cognitive dysfunction16% vs. 43%, χ2 = 5.079, P = 0.024 down: Inhibits lipopolysaccharide translocation | Randomized trialpostoperative days 1 and 2 | 60 peopleelderlyOlder adults; elderly patients undergoing spinal surgery; total intravenous anesthesia | Frontiers in pharmacology, Oct 9, 2018 |
down: Decreases postoperative cognitive dysfunction23.7% vs 45.9% incidence down: Decreases S-100β protein down: Decreases IL-6 | Randomized trialpostoperative days 1 to 3 | 80 peopleelderlyOlder adults; after one-lung ventilation surgery with neoadjuvant chemotherapy | Metabolic brain disease, Nov 9, 2016 |
What did studies of ulinastatin find?
6Studies of ulinastatin measured 6 outcomes; the most studied are postoperative cognitive dysfunction (4 studies) and inflammation (3).
Postoperative cognitive dysfunction
downin humans4OR 0.28
4 studies
Postoperative cognitive dysfunction
downin humans4OR 0.28
Ulinastatin prevents postoperative cognitive dysfunction in humans (compared with dexmedetomidine) (OR = 0.28, 95% CI 0.10 to 0.71).
“ulinastatin may be more effective in preventing POCD than dexmedetomidine [odds ratio (OR) = 0.28, 95% confidence interval (CI) = (0.10, 0.71)]”
Human trialcompared with dexmedetomidine
Brain and behavior
Ulinastatin decreases postoperative cognitive dysfunction in humans (elderly patients undergoing spinal surgery; total intravenous anesthesia) (16% vs. 43%, χ2 = 5.079, P = 0.024).
“Ulinastatin infusion significantly reduced the incidence of POCD in elderly patients undergoing spine surgery”
Human trialelderly patients undergoing spinal surgery; total intravenous anesthesia10,000 units/kg then 5000 units/kg
Frontiers in pharmacology
Ulinastatin decreases postoperative cognitive dysfunction in humans after one-lung ventilation surgery with neoadjuvant chemotherapy (23.7% vs 45.9% incidence).
“The U group had a lower incidence of POCD than C group (23.7 % versus 45.9 %, P = 0.043).”
Human trialafter one-lung ventilation surgery with neoadjuvant chemotherapy10,000 U/kg before anesthesia, then 5000 U/kg dailypostoperative days 1 to 3n = 80
Metabolic brain disease
Ulinastatin prevents postoperative cognitive dysfunction in humans (perioperative use in elderly patients under general anesthesia).
“effectively prevent the occurrence of POCD and reduce its incidence”
Reviewperioperative use in elderly patients under general anesthesia
Medicine
Inflammation
downin humans3
3 studies
Inflammation
downin humans3
Ulinastatin inhibits inflammation in humans (compared with control group following surgery).
“The elderly patients in ulinastatin group exhibited lower serum LPS, IL-6, CRP, and MMP-9 concentrations”
Human trialcompared with control group following surgery
Frontiers in pharmacology
Ulinastatin decreases inflammation in humans following surgery.
“patients in the ulinastatin group have lower levels of TNF-α, S100β, CRP, and IL-6 and higher level of IL-10 in serum following surgery”
Reviewfollowing surgeryserum
Frontiers in neuroscience
Ulinastatin decreases inflammation in humans (perioperative use in elderly patients under general anesthesia).
“The use of Ulinastatin in perioperative period can significantly reduce the inflammatory level of elderly patients after general anesthesia”
Reviewperioperative use in elderly patients under general anesthesia
Medicine
Lipopolysaccharide translocation
downin humans1
1 study
Lipopolysaccharide translocation
downin humans1
Ulinastatin inhibits lipopolysaccharide translocation in humans (elderly patients undergoing spinal surgery).
“Systemic inflammation and translocation of LPS were inhibited by the infusion of ulinastatin”
Human trialelderly patients undergoing spinal surgery
Frontiers in pharmacology
IL-10
upin humans1
1 study
IL-10
upin humans1
Ulinastatin increases IL-10 in humans (on postoperative day 3).
“On postoperative day 3, compared with C group, the level of CRP in U group was lower, while that of IL-10 was higher.”
Human trialon postoperative day 310,000 U/kg before anesthesia, then 5000 U/kg dailypostoperative days 1 to 3n = 80
Metabolic brain disease
IL-6
downin humans1
1 study
IL-6
downin humans1
Ulinastatin decreases IL-6 in humans (postoperative).
“The postoperative concentrations of S-100β protein, IL-6, and CRP in U group were lower than those in C group.”
Human trialpostoperative10,000 U/kg before anesthesia, then 5000 U/kg dailypostoperative days 1 to 3n = 80
Metabolic brain disease
S-100β protein
downin humans1
1 study
S-100β protein
downin humans1
Ulinastatin decreases S-100β protein in humans (postoperative).
“The postoperative concentrations of S-100β protein, IL-6, and CRP in U group were lower than those in C group.”
Human trialpostoperative10,000 U/kg before anesthesia, then 5000 U/kg dailypostoperative days 1 to 3n = 80
Metabolic brain disease
What is ulinastatin linked with?
1Studies link ulinastatin with postoperative cognitive dysfunction.
Postoperative cognitive dysfunction
downin humans1RR 0.29
1 study
Postoperative cognitive dysfunction
downin humans1RR 0.29
Ulinastatin lowers the risk of postoperative cognitive dysfunction in elderly patients undergoing surgery (RR = 0.29, 95% CI 0.21-0.41).
“ulinastatin significantly reduced the incidence of POCD [risk ratio (RR) = 0.29, 95% CI 0.21-0.41, test of RR = 1: Z = 7.05, p < 0.00001]”
Reviewin elderly patients undergoing surgery
Frontiers in neuroscience
Who is developing ulinastatin?
1 company: Techpool Bio-Pharma.
- Companies
- Techpool Bio-PharmaPhase 1ulinastatin
Trial sponsors
Company1 trialPhase 140 people